Generating Research Impact through Innovation, Commercialization & Entrepreneurship
McMaster is one of the world’s top universities for global and industry impact. Our reputation for innovation is powered by the creative minds that make up our entrepreneurial ecosystem – from our faculty and staff to our undergraduate and graduate students, industry partners, hospitals, and community collaborators. McMaster innovators are focused on finding solutions that matter to people and the planet – and we’re proud to support their journeys every step of the way.
This year, our founders reached new heights. Fusion Pharmaceuticals was acquired for $2 billion by AstraZeneca in a historic agreement that aims to advance cancer care for patients worldwide. Industry leaders consistently turn to our researchers to find real-world solutions to pressing global challenges. This year’s Times Higher Education University Impact Rankings recognizes McMaster as a global leader in industry and research impact, one of only 34 universities in the world to score a perfect 100 for its engagement with the private sector and contribution to economic development.
McMaster’s entrepreneurs came together throughout the year to celebrate, inspire and empower one another. By participating in new partnerships, fellowships, programs and events – including those introduced by McMaster’s new Entrepreneurship Academy – our student and faculty entrepreneurs worked across disciplines to convert their innovative ideas into high-value products and services. In the process, they found ways to inspire and uplift their colleagues in the early stages of their entrepreneurial journeys, ensuring an even brighter future of innovation and impact at McMaster and within our local and global communities.
The McMaster Industry Liaison Office (MILO) helped facilitate unprecedented growth in innovation. In 2023-24, MILO evaluated over 100 disclosures, secured 60+ issued patents, invested $768,000 in three startup companies through the McMaster Seed Fund, and supported 300+ partnerships.
MILO and Office of the Vice-President, Research are thrilled to share these highlights from an impactful year of research, innovation, commercialization, and entrepreneurship. We’re proud to support and celebrate our entrepreneurs’ groundbreaking work and look forward to launching new resources and initiatives in the future.
Leyla Soleymani
Associate Vice-President, Research (Commercialization & Entrepreneurship)
Gay Yuyitung
Executive Director, McMaster Industry Liaison Office
Partnerships & Collaboration
At McMaster, we proudly partner with industry, non-profit organizations and government bodies to find solutions to our most pressing global concerns. We work across disciplines and borders to address complex challenges, improve products and processes, and develop new policies and guidelines that promote a cleaner and healthier future for all.
The McMaster Industry Liaison Office (MILO) plays an instrumental role in securing impactful partnerships between our researchers and their collaborators. MILO helps researchers secure funding from industry by identifying and evaluating applications for matching grant programs, such as the Natural Sciences and Engineering Research Council’s (NSERC) partnership programs, the Ontario Centre of Innovation’s (OCI) collaborative programs and Mitacs’ funding programs.
MILO also assists researchers in applying for commercialization funding programs, such as NSERC’s Idea-to-Innovation, Canadian Institutes of Health Research (CIHR) Commercialization grants, and OCI’s Market Readiness Co-Investment Fund.
Showcase of approximately 15 startups/ventures that have flourished within the McMaster ecosystem.
$53M+
Research Funding Administered
300+
Partnerships Supported
750+
Agreements Negotiated
Information Box Group
McMaster health researchers awarded commercialization support through LeapRX Learn more about this initiative on LinkedIn
Two McMaster researchers received support from LeapRX to advance health research and therapeutics, in collaboration with leading healthcare and pharmaceutical company, Novo Nordisk, and drug discovery accelerator, Empire Discovery Institute (EDI). Created by Novo Nordisk and EDI in 2022, the LeapRX program is designed to help researchers commercialize their breakthrough discoveries through access to funding, expert pharma guidance and complementary expertise.
A team of researchers led by professor of medicine, Joan Krepinsky, is developing a novel therapeutic for diabetic kidney fibrosis. As part of the LeapRX program, EDI is supporting the project with their drug development expertise and Novo Nordisk is lending their deep understanding of preclinical and clinical R&D to help advance the novel therapeutic. The team has also worked with the McMaster Industry Liaison Office (MILO) to file patents, create a commercialization plan and establish a path forward for drug development.
Greg Steinberg, co-director of McMaster’s Centre for Metabolism, Obesity and Diabetes Research (MODR), is leading a project focused on novel approaches to weight loss for those suffering from obesity. EDI and Novo Nordisk are working closely with Steinberg’s team to develop a translational plan based on the results of the project and ensure therapies can reach patients who will benefit from them most.
Understanding the impacts of cleaning products on freshwater ecosystems
An international research project led by McMaster biology professor Karen Kidd, funded by the Natural Sciences and Engineering Research Council of Canada (NSERC) and Mitacs, and facilitated by the McMaster Industry Liaison Office (MILO), is assessing the impact of disinfectant cleaning products on freshwater ecosystems.
In recent years, studies have shown there is an increased use of cleaning products and personal care products, leading to their widespread presence in municipal wastewater effluents and surface waters in Canada. Researchers from six Canadian universities and two United Kingdom universities have partnered with the International Institute of Sustainable Development – Experimental Lakes Area (IISD-ELA) and Fisheries and Oceans Canada to design and conduct a study on impacts on aquatic life. Specifically, researchers will be examining the effect of quaternary ammonium compounds (QACs), a commonly-used group of antimicrobials which are toxic to many of the species that support aquatic food webs, such as algae.
IISD-ELA is a natural laboratory comprised of 58 small lakes and their watersheds, located in a sparsely populated region of Northwestern Ontario. By studying these small lakes, scientists can examine how all aspects of the ecosystem respond. The project team will conduct a series of lab studies and in-lake enclosure studies – leading up to a whole-lake experiment at the IISD-ELA –to advance understanding of the persistence, uptake and toxicity of QACs in freshwater ecosystems. Findings from these real-world experiments will support the development of risk assessments, monitoring programs and regulations on the use of these compounds, with the overall aim of maintaining healthy aquatic ecosystems.
McMaster engineering professors awarded $4.7M to lead cutting-edge quantum research Read More at Brigher World News
Three projects led by five McMaster engineering physics professors have received a total of $4.7 million to advance research on quantum technologies, an emerging area of specialization that is poised to revolutionize various fields – from computing and communication to sensing and cryptography – and transform how people work and live in Canada and around the world. The funding is awarded through the National Sciences and Engineering Research Council’s (NSERC) Alliance Grants program, which encourages university researchers to collaborate with partner organizations from across the private, public or not-for-profit sectors.
- Rafael Kleiman, professor and department chair, is working with SolidState AI to develop a hybrid superconducting-photonic platform for quantum computing.
- Chang-qing Xu, professor, is collaborating with OZ Optics Ltd. and Optiwave Systems Inc. on the development of compact, efficient and robust quantum sources to improve quantum communication networks.
- Ryan Lewis, assistant professor, has partnered with Xanadu to investigate on-chip entangled photon generation and detection.
All three projects will advance Canada’s National Quantum Strategy, which seeks to ensure the country remains a world leader in the development, deployment and use of quantum computing hardware and software to the benefit of Canadians.
Partnering to build age-friendly communities and health resources for older Canadians Learn More About ABLE Village
Older adults often face barriers to accessing important resources and age-friendly spaces that foster community, promote social connectivity and enhance their overall health and well-being.
The McMaster Industry Liaison Office (MILO) has supported two key projects over the past year aimed at addressing complex issues related to health and longevity in Canada’s aging population. The first project, ABLE Village, is a digital platform that offers social, art and recreational activities for older adults. The virtual village acts as a space where older adults can socialize, learn, make, play and grow – practices which have been shown to foster vibrant aging and longevity. Led by McMaster researcher, Paula Gardner, ABLE Village is a Pan-Canadian project that involves over 20 organizations, including several academic institutions and not-for-profit community partners.
The second is a community-based project led by the Hamilton Council on Aging (HCoA), the Gilbrea Centre for Studies in Aging at McMaster and the Geras Centre for Aging Research, funded by the Public Health Agency of Canada (PHAC). The partners are working together to develop engagement and empowerment groups comprised of persons living with dementia. Using best practices in knowledge translation, the project will establish new partnerships and strengthen existing partnerships in the communities of Six Nations of the Grand River, the Halton Region and Hamilton, with the aim of introducing campaigns that improve the quality of life for people living with dementia and their care givers.
MILO helped facilitate the partnership agreements for both projects, ensuring all participating organizations, academic institutions and community partners can collaborate effectively and synergize their expertise and resources to enact meaningful change. As Canada’s aging population continues to grow, McMaster and MILO are committed to finding new avenues to transfer research results to society, where they can help shape policies and practices that will strengthen communities and improve the lives of Canadians.
Turning Research into Impact
McMaster spinout company Fusion Pharmaceuticals acquired for $2 billion (US) in landmark deal with AstraZeneca
Fusion Pharmaceuticals, a cancer therapy and diagnostics company, has been acquired by global pharmaceuticals giant AstraZeneca in a deal valued at $2 billion (US) – one of the highest-valued acquisitions of a Canadian university spinout company in history.
Founded by McMaster professor of Chemistry and Chemical Biology, John Valliant, and a spinout of McMaster-based Centre for Probe Development and Commercialization, Fusion develops next generation radioconjugates (RCs) as precision medicine. RCs combine the precise targeting of antibodies or small molecules with potent medical isotopes to deliver radiation directly to cancer cells. The acquisition will strengthen AstraZeneca’s position as a leader in personalized medicine — developing cancer therapeutics for more effective treatment with reduced toxic side effects.
“This transaction is recognition of Fusion’s innovative science, and gives us a unique opportunity to accelerate the development of next generation radioconjugates with the aim of transforming patient outcomes,” says Valliant.
Fusion’s research and manufacturing operations will continue in Canada, at the company’s state-of-the-art facility at McMaster Innovation Park. Fusion will also continue to partner with McMaster to train graduate students in the development, testing and use of radiopharmaceuticals to identify and treat cancers.
For many years, McMaster has been committed to supporting entrepreneurship and innovation, on our campus and in our region. This agreement speaks to our researchers’ ability to convert their world-class research into innovations that generate economic activity, create jobs and, most important, improve health outcomes for patients in Canada and globally.
– David Farrar
New resources and programs for McMaster’s entrepreneurship community
In 2023-24, McMaster made significant additions to its commercialization and entrepreneurship portfolio. The university is investing $900,000 over the next two years in a new suite of programs, events and resources. These initiatives are designed to inspire, support, and reward established and aspiring McMaster entrepreneurs as they work to transform their research breakthroughs into high-value products and services.
Leyla Soleymani, professor of engineering physics and co-founder of FendX Technologies, joined the Office of the Vice-President, Research (OVPR) as McMaster’s associate vice-president, research (commercialization & entrepreneurship). With the goal of enhancing McMaster’s unique entrepreneurial training, research and translation pipeline, the OVPR, the Office of the Provost and Vice-President (Academic), and the McMaster Industry Liaison Office (MILO) established the McMaster Entrepreneurship Academy. The Academy now hosts several programs, including the Professor Entrepreneur Fellowship, Postdoc Entrepreneur Fellowship, Innovation Matchmaking program, and Mentorship program. Additionally, other resources are currently in development to facilitate increased access to lab space for entrepreneurs. More than 200 early-stage and established entrepreneurs, investors, mentors and ecosystem members engaged with these programs in 2023-24.
The Professor Entrepreneur Fellowship provides full-time faculty members with a one-year release from teaching one course, allowing them to dedicate more time to their entrepreneurial endeavors. In March 2024, eleven faculty members participated in the pitch competition at the Forge, and three of them – Maryam Aramesh, Wael El-Dakhakhni and Jim Cotton – were awarded the Fellowship.
The Innovation Matchmaking program facilitates collaboration between researchers from McMaster and its affiliated hospitals. These teams work together to develop and commercialize technology solutions addressing pressing health challenges. In the program, eight multidisciplinary research teams pitched their cutting-edge health technologies in June 2024, and four were awarded $75,000 in prep-funding that can be used to build their ventures.
The Academy also helped organize the first-ever Made-at-Mac event in March 2024, which celebrated McMaster student and faculty entrepreneurs and the launch of the University’s dedicated entrepreneurship website – a one-stop digital hub with resources, programs, services and supports for community members at every stage of their entrepreneurial journey.
McMaster partners with Celesta Capital to accelerate deep tech innovation and commercialization
A new partnership between McMaster and Celesta Capital is cultivating the next generation of deep tech innovations at McMaster and in the broader Canadian research and startup ecosystem. Headquartered in Silicon Valley, Celesta Capital is a global multi-stage deep technology venture capital firm, with a portfolio of more than 100 early-stage technology investments. The partnership will allow the university to tap into Celesta’s expertise and accelerate the commercialization of deep tech — cutting-edge technologies built on science and engineering innovations — developed by McMaster researchers.
Celesta will support McMaster-affiliated startups and researchers in commercializing their intellectual property (IP). They will also facilitate increased interactions and opportunities between the technology and venture capital hubs of Canada, Silicon Valley, India and beyond to help McMaster innovators move their research out of the lab and into the hands of those who can put it to work in the world.
Innovation Showcase 2024
We invite you to join us in-person for Innovation Showcase 2024 on November 19. Hosted by the McMaster Industry Liaison Office at the McMaster Innovation Park (175 Longwood Road South, Hamilton)
Since 2008, this annual event has been a platform for exhibiting McMaster’s top innovations and commercialization achievements. Whether you’re an internal stakeholder or part of the broader McMaster community, this day promises exciting insights and valuable networking opportunities. Our agenda includes expert panel discussions, a trainee pitch competition, innovator awards, and an inspiring keynote speaker.
McMaster Seed Fund
Since its inception in 2021, the McMaster Seed Fund (MSF) has helped McMaster researchers transfer their innovative ideas from the lab to the market. The MSF has invested over $2.7 million in eight startup companies to date, driving economic and social impact in the Hamilton region and beyond. Together, MSF recipients’ products and services have been piloted and installed in hospitals, clinics and businesses across Canada and the world. They have attracted 34 new employees and raised over $5.6 million in combined revenue, post-MSF investment.
The three latest MSF awardees – HARvEST, A.I. Vali and Esphera SynBio – received $256,000 each in 2023-24 to advance their groundbreaking technologies in the energy and health sectors – from decarbonizing the restaurant industry with waste heat recycling to enhancing endoscopy analysis using AI and developing new treatments for infectious disease and cancer.
MSF applications are managed by the McMaster Industry Liaison Office (MILO) and vetted by an Investment Committee comprised of successful entrepreneurs, early-stage investors and top executives – all external to the University. MILO is proud to support applicants by facilitating pitch practices, conducting due diligence assessments, and making connections to advisors or potential partners.
2023-24 MSF Awardees
HARvEST Visit HARvEST's website
Co-founded by mechanical engineering professor, James Cotton, and research lab manager at the McMaster Institute for Energy Studies, Jeffrey Girard, HARvEST aims to support decarbonization of the restaurant industry with their fuel-less, carbon-free hot water heating system. The HARvEST platform, developed through a $1.7 million research collaboration between McMaster, Pizza Pizza Limited, and Enbridge Gas, has secured purchase order commitments after successful demonstrations in three Ontario Pizza Pizza restaurants. The system captures waste heat from cooking appliances, such as ovens and fryers, to offset energy consumption in other parts of the restaurant, including water heating.
A.I. Vali Visit A.I. Vali's website
Medical device startup A.I. VALI Inc. – cofounded by McMaster professor of medicine and gastroenterologist, David Armstrong – received funding from MSF to advance its AI-driven platform AIDREA™, which uses interactive machine learning to document and analyze endoscopy videos in real-time. The company was named one of the top 10 AI in Healthcare Solution Providers by MedHealth Outlook in 2024 and recently secured $806K in funding and received a $150K grant to lead a procurement project at CHUM hospital in Montreal, Quebec.
Esphera SynBio Visit Esphera SynBio's website
Co-founded by associate professor of medicine, Brian Lichty, biotech startup Esphera SynBio has developed a novel therapeutic technology that leverages exosomes to deliver defined payloads – including enzymes and RNAs – to targeted cells in the body. The platform is designed to enhance existing immunotherapy and vaccine technologies and aid in gene therapy, enzyme replacement therapy and cancer immunotherapy. Since its launch in 2022, the company has raised over $2 million (USD) in funding.
Startups
McMaster has been instrumental in the establishment of over 300 startup companies founded by our talented students, faculty, staff and alumni. These companies are not only driving innovation and economic growth but are also shaping the future of health, science and technology in ways that will have a lasting impact on society. Here’s a look at a few Made-at-Mac ventures that are solving real-world problems.
Information Box Group
Afynia Visit Afynia's website
Co-founded by Lauren Foster, professor emeritus in the department of obstetrics and gynecology, and McMaster graduate Jocelyn Wessels, Afynia Laboratories is accelerating the pathway to endometriosis diagnoses for the millions that suffer from the historically underdiagnosed disease. Afynia’s microRNA-based molecular screening test, EndomiR, consists of a routine blood test, making it faster and cheaper than existing endometriosis diagnostic tools. At the beginning of 2024, Afynia closed a $2-million CAD round of pre-seed funding to develop and begin bringing EndomiR to market. EndomiR is currently being used in several Canadian fertility clinics as part of its pilot market launch, and Afynia surpassed $100,000 in revenue in 2024.
OrganoBiotech Visit OrganoBiotech's website
OrganoBiotech is transforming the way drugs are developed by integrating high-throughput, human-centric Organ-on-a-Chip models with the analytical power of machine learning. The company provides a suite of tissue culture platforms and equipment that enable users to become effective model developers. In 2021, OrganoBiotech raised $200,000 USD in seed funding. They currently offer three tissue culture platforms – including a new product introduced in 2023, AngioTEER. The company is currently working with end users, including Merck and United Therapeutics, to advance use of their OrganoPlatforms, which provide tissue-specific customization, giving users greater freedom to develop models for different tissue types.
Agapyo Visit Agapyo's website
Incorporated in September 2023, Agapyo Inc. is helping to address the global plastic waste crisis through their 100% plant-based thermoplastic technology, jam™. Using proprietary IP developed by chemical engineering professor, Michael Thompson, the company has developed a biodegradable and bio-sourced bioplastic technology that has comparable properties to ABS – a petroleum-based plastic commonly used in consumer products. Unlike ABS, jam™ can be melted, molded and, at end-of-life, made back into soil – leaving behind zero trace of microplastics in the environment.
Since incorporation, Agapyo Inc. has won the Climate Solution Start-up Prize ($150k) and BDC’s Women in Clean Tech Prize ($150k). The company has signed MOUs with strategic collaborators, scaled-up the production of jam™ and validated it in an industry-standard, injection-molding machine.
Outreach & Education
McMaster’s new online course teaches fundamentals of intellectual property
Having a basic understanding of intellectual property is key to navigating research collaborations and the research commercialization process. That’s why the McMaster Industry Liaison Office (MILO) launched a free Intellectual Property e-learning course in Fall 2023 – available to McMaster staff, students and faculty across all disciplines.
The course consists of three modules designed to help participants enhance their understanding of fundamental IP concepts, develop effective IP strategies and discover how to access additional IP and research commercialization support from MILO. These self-paced, interactive learning exercises are embedded with quizzes to test participants’ knowledge, as well as activities and case studies to apply what they’ve learned to real-world scenarios.
Since its inception, 230 people have participated in the course and thousands have accessed MILO’s publicly available IP Guides. With more fulsome knowledge of IP practices and law, McMaster innovators can enhance the impact and transformational value of their ideas and continue to advance innovative solutions that tackle some of our most pressing global challenges.
Investing in our Innovators
MSc student Justin Prez awarded inaugural Whelen Fellowship
Established in 2023, the John Whelen Family Innovation Advancement Fellowship Fund matches McMaster students with a startup company to benefit both the student in developing entrepreneurial skills, and the company to move their innovations closer to market.
Master’s student Justin Prez was awarded the inaugural fellowship to work with McMaster startup company A.I. VALI and help them advance their groundbreaking medical imaging technology, AIDREA™. With a background in software development and biomedical engineering, Prez worked alongside the A.I. VALI team to test and improve the AIDREA™ prototype, bringing the device closer to commercialization.
AIDREA™ revolutionizes the way endoscopies are performed by supporting real-time image capture and voice-to-text annotations. Prez led integration testing for the software, ensuring robust performance and reliability, and assessed metrics like verbal annotation accuracy to refine the device’s accuracy and functionality. He also provided support at multiple hospital sites for AIDREA™ setup and on-the-fly debugging and led product demonstrations to investor groups and potential clients, with the aim of raising funding and sales to support A.I. VALI’s continued growth.
The Forge and The Sam and Roma Mercanti Foundation Partner to Empower Medical Startups with $2,500 Awards
A new funding initiative established by The Forge and The Sam and Roma Mercanti Foundation will support innovative startups across the sectors. The inaugural funding was awarded to two medical startups – Respyra Technologies and Medium AI. Each company received $2,500 to advance their work in healthcare innovation.
Respyra specializes in innovative solutions for airway management. Many intubations are unsuccessful on the first attempt, leading to increased adverse events and costing valuable time for clinicians. Respyra is addressing this critical issue with the development of an intubation aid that enables smooth intubation of difficult airways on the first attempt. The funding and support provided by the Forge and the Sam and Roma Mercanti Foundation will fuel the company’s development of a scalable business model for their game-changing technology.
The second recipient, Medium AI, is making strides in the automation and streamlining of medical documentation. The company has developed a multilingual medical scribe system that automates the time-consuming process of medical documentation, allowing healthcare providers to spend more time with their patients. The $2,500 will be used to further develop their iOS version, which will launch later this year.
By combining The Forge’s resources and mentorship programs with the financial support provided by the Sam and Roma Mercanti Foundation, the partners will continue to help startups like Respyra Technologies and Medium AI achieve their goals and advance innovations with impact.
We want to extend our deepest gratitude to the John Whelen Family Innovation Advancement Fellowship Fund and The Sam and Roma Mercanti Foundation for their forward-thinking donations. It is with their support that we are able to create impactful opportunities.
We remain committed to expanding our network of donors and partners to ensure the continued growth of initiatives like this one, building a brighter future together.
Licensing
Licensing a healthcare tool to improve meaningful end-of-life support for patients and their families
Developed by a team of McMaster researchers, counselors, physicians, and nurses, the 3 Wishes Project is focused on facilitating compassionate end-of-life care and support for patients and their families. With the goal of improving care for critically ill Canadians and fostering a more empathetic healthcare environment, the Project carries out three wishes for dying patients to bring them peace and positive experiences in the final days of their life.
The 3 Wishes Project was originally implemented in St. Joseph’s Healthcare Hamilton in 2013, where it became an important part of the high-quality care offered to all dying patients. Since then, the 3 Wishes team has successfully implemented and evaluated the project at ICUs in Toronto, Los Angeles and Vancouver, with the help of their Start Up Guide.
The 3 Wishes Project Start Up Guide is designed to help frontline ICU staff adapt the 3 Wishes Project to their own healthcare units. The guide is now licensed through the McMaster Industry Liaison Office (MILO), with the main goal of making this low-cost, high-impact project reach a broader audience of hospitals and patients worldwide.
New modelling software will help steel industry better understand and optimize production process
A team of researchers led by materials science and engineering professor, Hatem Zurob, has developed a simulation platform that can help industry better understand and optimize how steels are produced. Developed in collaboration with McMaster’s Steel Research Centre and the American Iron and Steel Institute, Calypso HSMM is a ‘digital twin’ that models the hot rolling process, enabling industry to study the changes that alloyed steels undergo during production on the micro-scale, and test new steel compositions in a more cost-effective way. The platform can also serve as an innovative tool to support the training of materials engineers.
Calypso HSMM is currently available through a university portal and Zurob and team have plans to build the software into a startup company, making it widely available to industry in North America and around the world. The platform has received positive feedback from industry experts who have used the pre-release versions. The team will release the first build of Calypso HSMM in Q4 of 2024 and will continue to seek opportunities to expand their user base to the hundreds of hot rolling mills and plate mills worldwide.
Metrics – Fiscal Year 2023-24
Commercialization Revenue
Including royalties, licensing fees, equity
Disclosures
Total Disclosures
| Year | Total number of disclosures |
|---|---|
| 2021 | 88 |
| 2022 | 87 |
| 2023 | 87 |
| 2024 | 103 |
Disclosures by Faculty
| Year | Faculty of Science | Faculty of Engineering | Faculty of Health Sciences | Other Faculties/Hospitals |
|---|---|---|---|---|
| 2021 | 11 (27.50%) | 45 (22.50%) | 43 (21.50%) | 14 (7.00%) |
| 2022 | 20 (33.33%) | 39 (19.50%) | 40 (20.00%) | 14 (7.00%) |
| 2023 | 8 (13.33%) | 46 (23.00%) | 37 (18.50%) | 15 (7.50%) |
| 2024 | 11 (18.33%) | 53 (26.50%) | 46 (23.00%) | 24 (12.00%) |
Breakdown of Inventors
….
| Category | Percentage | Count |
|---|---|---|
| Faculty | 43% | 122 |
| Postdocs & Research Staff | 32% | 90 |
| Undergraduate Student | 3% | 9 |
| Graduate Student | 21% | 60 |
Quick Stats
Achievements from Fiscal Year 2023-24
disclosures
total patent applications filed (all countries)
patents issued
total licenses executed
in royalty and/or licensing revenue
in knowledge mobilization revenue
Over the past 10 years
50+ startup companies created
Technology Spotlight
Information Box Group
Phage-loaded Hydrogel Treatment for Bone and Implant Infections Read the tech brief on Phage-loaded Hydrogel
Phage therapy uses viruses to target and kill harmful bacteria, offering a precise, minimally invasive, alternative to antibiotics with high efficacy.
Researchers at McMaster University have developed a phage-loaded injectable hydrogel treatment for osteomyelitis infections. The phages are delivered to the site of infection to treat the bacterial infection, while the hydrogel promotes bone tissue regeneration.
Photo credit: Emily Brown; CC BY-SA
A Point-of-Care Test to Quantify Tranexamic Acid Levels in Patient Samples Read the tech brief on the TXA Levels Point-of-Care Test
Researchers at McMaster University have developed a point-of-care assay for measuring tranexamic acid (TXA) levels in patient plasma. This innovative method provides a rapid, simple solution for monitoring TXA, addressing the current lack of pharmacokinetic and pharmacodynamic data and aiding clinicians in optimizing dosing and treatment strategies for various bleeding conditions.
Ultra-thin SiGe layers enabling III-V epitaxy on Si Read the tech brief on Ultra-thin SiGe layers
Researchers at McMaster University have developed an innovative GaAs/Si1-xGex/Si(111) heterostructure fabrication process, overcoming integration challenges of III-V semiconductors on silicon. Using a novel Ge oxidative solid-phase epitaxy method, this process enables high-performance GaAs-based lasers and photodetectors on Si, optimizing efficiency for data communication and optical interconnects, and enhancing energy conversion in advanced multijunction solar cells.
Prognostic Marker for Acute Myeloid Leukemia (AML) Relapse Read the tech brief on the Prognostic Marker for AML Relapse
Researchers at McMaster University have discovered a unique cell population—AML Regeneration Enriched Cells (RECs)—that drive leukemia relapse post-chemotherapy and provide new insights into AML progression. This breakthrough has led to the development of a novel prognostic method for predicting patient survival and treatment outcomes, potentially transforming AML care.
Issued Patents
| Patent Name | Inventors | Countries |
|---|
